Connect with us

Technology

Rocket One Reports Approximately $8.4 Million in Cash and Cash Equivalents and Outlines Strategy Across AI Infrastructure, Spintronic Computing for Space and Defense Markets

Published

on

HOBOKEN, N.J., June 15, 2026 /PRNewswire/ — Rocket One, Inc. (Nasdaq: RKTO) (“Rocket One” or the “Company”), a company focused on advanced computing technologies and next-generation infrastructure for the space economy, today provided an update to its shareholders.

Dear Fellow Shareholders,

The past several months have marked a transformative period for our Company. Following our transition from Hoth Therapeutics to Rocket One Inc. (Nasdaq: RKTO), we have begun executing a strategy focused on advanced computing, artificial intelligence infrastructure, space systems, and defense-related technologies.

We believe the coming decade will be defined by the convergence of artificial intelligence, space infrastructure, and national security modernization. Each of these markets requires increasingly powerful, efficient, and resilient computing architectures. Rocket One was created to pursue opportunities at this intersection.

Today, Rocket One is building a foundation that includes exclusive licenses to technology, a growing network of technical and strategic advisors, and a long-term vision focused on next-generation computing technologies and their potential applications across commercial, space, and defense markets.

Financial Position

As of June 12, 2026, Rocket One had approximately $8.4 million in cash and cash equivalents. 

The Company’s cash position reflects proceeds received through its previously disclosed at-the-market (“ATM”) equity program. Additional information regarding shares issued and proceeds received under the ATM program is available in the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.

Building Rocket One

Artificial intelligence is rapidly becoming one of the largest infrastructure markets in the world. At the same time, the growth of satellite networks, edge computing, and national security technologies is creating demand for computing architectures that deliver greater performance while consuming less power.

Rocket One believes that the same characteristics that make advanced computing technologies attractive for AI infrastructure—including lower power consumption, reduced memory movement, improved efficiency, and enhanced performance—may also prove valuable in future space and defense environments where power, thermal management, reliability, and operational efficiency are critical design constraints.

Our objective is to position Rocket One at the convergence of these trends through a combination of acquiring rights to certain intellectual property, entering into strategic partnerships, developing technical expertise, and employing disciplined capital allocation and targeted growth initiatives.

Exclusive Spintronic and Nanomagnetic Computing Technology

On May 15, 2026, Rocket One entered into two exclusive license agreements relating to spintronic and nanomagnetic computing technologies designed for artificial intelligence and data-center applications.

The licensed intellectual property includes novel all-spin matrix multiplication and nanomagnetic computing architectures intended to address some of the most significant challenges facing modern artificial intelligence, including power consumption, memory bottlenecks, and computational efficiency.

Unlike conventional silicon-based approaches, spintronic computing utilizes the magnetic properties of electrons to process and store information. The underlying technologies are designed to leverage nanomagnetic structures that may enable highly energy-efficient computing, reduced data movement, and new approaches to AI hardware acceleration.

Rocket One believes these technologies represent a compelling opportunity within the rapidly growing AI infrastructure market that could provide a foundation for future advanced-computing applications. Published research associated with the licensed technology has demonstrated the potential for substantial improvements in computational efficiency and power consumption relative to conventional architectures.

Management believes that the characteristics associated with spintronic and nanomagnetic computing—including potential improvements in power efficiency, data movement, and computational performance—may be relevant to future space and defense computing environments, where power, thermal management, reliability, and operational efficiency are critical considerations.

The Company is evaluating development pathways, strategic partnerships, and commercialization opportunities designed to advance these technologies toward practical applications in artificial intelligence infrastructure, advanced computing, space systems, and defense-related technologies.

Expanding Our Advisory Network

Rocket One continues to strengthen its leadership and advisory capabilities through the addition of distinguished experts across advanced computing, aerospace, military, and spaceflight disciplines.

Dr. Supriyo Bandyopadhyay serves as Lead Technical Advisor for AI Nanomagnetic Technology and is a recognized professor and researcher who has worked in the areas of spintronic and nanomagnetic computing research.

Major General Malcolm B. Frost (Ret.) recently joined Rocket One’s Space and Defense Advisory Board. General Frost brings more than three decades of military leadership experience and strategic expertise across defense operations, national security, and emerging technologies.

Colonel Robert “Shane” Kimbrough (Ret.) joined Rocket One’s Space and Defense Advisory Board. Colonel Kimbrough is a former NASA astronaut and former Commander of the International Space Station who brings firsthand experience in human spaceflight, orbital operations, and the future of the space economy.

Together, these advisors strengthen Rocket One’s ability to evaluate opportunities across advanced computing, artificial intelligence, space infrastructure, and defense technologies.

Legacy Biotechnology Portfolio

While Rocket One has embarked on a new strategic direction, the Company continues to maintain ownership of the biotechnology assets developed under Hoth Therapeutics.

This includes HT-001, the Company’s clinical-stage program focused on the treatment of EGFR inhibitor-associated skin toxicities. The pharmacokinetic (PK) portion of the HT-001 Phase 2 clinical program has been completed, and the Company is currently awaiting finalized PK results. Additional portions of the Phase 2 program remain ongoing.

As management’s primary focus shifts toward the execution of Rocket One’s technology strategy, the Company is evaluating a range of strategic alternatives for its biotechnology assets, including HT-001 and its other candidates and intellectual property. These alternatives may include partnerships, licensing transactions, joint ventures, asset sales, or other strategic opportunities designed to maximize shareholder value.

No decision has been made regarding any specific transaction, and there can be no assurance that any partnership, licensing arrangement, or sale will occur. However, management believes the biotechnology portfolio represents a potentially valuable collection of clinical-stage assets and intellectual property that may be attractive to strategic partners while allowing Rocket One to focus on its long-term technology strategy.

Looking Ahead

Rocket One believes that meaningful value creation may come from a combination of internal technology development, strategic partnerships, licensing opportunities, and disciplined capital deployment.

In addition to advancing its licensed technology portfolio, Rocket One intends to evaluate strategic acquisitions, partnerships, and licensing opportunities that complement the Company’s focus on advanced computing, artificial intelligence infrastructure, space systems, and defense technologies.

Management believes the current market environment presents opportunities to identify technologies, intellectual property, engineering capabilities, and operating businesses that may accelerate Rocket One’s long-term growth objectives. The Company intends to remain disciplined in evaluating potential opportunities and will focus on transactions that strengthen its strategic positioning and enhance long-term shareholder value.

Our objective is to unlock value from both sides of the business—advancing Rocket One’s AI and advanced-computing strategy while exploring strategic alternatives that may maximize the value of our biotechnology portfolio.

We appreciate the continued support of our shareholders as we pursue this vision and work to build long-term value.

Sincerely,

Robb Knie  
Chief Executive Officer
Rocket One Inc.  
Nasdaq: RKTO

About Rocket One Inc.
Rocket One Inc. is focused on developing and commercializing infrastructure for the orbital economy, including next-generation nanomagnetic AI chip technology designed for radiation-tolerant, energy-constrained environments such as low-Earth orbit, deep-space platforms, and defense systems. The Company holds exclusive rights to certain technologies, including a nanomagnetic matrix multiplier architecture intended as a hardware accelerator for machine learning and AI workloads, and related magnetic memory technology with potential applications in radiation-tolerant computing for defense and space systems. The Company is also positioned to pursue opportunities in nano-launch systems and nanosatellite deployment. The Company’s biotechnology pipeline, including, but not limited to, HT-001, HT-KIT, HT-ALZ, and its GDNF-based metabolic program, will continue to be advanced under a wholly owned subsidiary.

Forward-Looking Statements
 This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the Company’s strategic repositioning, the development potential of the licensed technologies, the suitability of those technologies for orbital, defense, and other applications, anticipated future operations and market opportunities. You should not place reliance on these forward-looking statements, which include words such as “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project” or similar terms, variations of such terms, or the negative of those terms. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These forward-looking statements are based on the Company’s current expectations and assumptions and are subject to numerous risks and uncertainties, including, without limitation: the early-stage nature of the licensed technologies, which have not been fabricated as integrated devices, validated in space environments, or qualified for any commercial or government program, and the absence of any commercial product; the substantial additional capital the Company will require to fabricate, test, and qualify the licensed technologies, including for radiation tolerance and space deployment; the long development timelines associated with novel semiconductor and materials platforms; competition from larger, better-funded and well recognized companies in the semiconductor, AI hardware, space, and defense computing sectors; the Company’s ability to recruit qualified leadership and technical personnel in nanomagnetic devices, semiconductor engineering, and aerospace systems; the Company’s ability to comply with diligence milestones under the Virginia Commonwealth University license agreements, the failure of which could result in loss of license rights; intellectual property risks; export control and government contracting risks associated with defense and space applications; and the risks inherent in a strategic pivot. Additional risk factors are described in the Company’s filings with the Securities and Exchange Commission (“SEC”) including the Company’s most recent Annual Report on Form 10-K and the Company’s other filings made with the SEC. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. The Company may not realize its expectations, and its beliefs may not prove correct. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as the Company’s current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. The Company cannot guarantee future results, events, levels of activity, performance, or achievements. The Company does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.

Investor Contact
LR Advisors LLC
Email: investorrelations@rocketone.space
Phone: (678) 570-6791
www.rocketone.space

View original content to download multimedia:https://www.prnewswire.com/news-releases/rocket-one-reports-approximately-8-4-million-in-cash-and-cash-equivalents-and-outlines-strategy-across-ai-infrastructure-spintronic-computing-for-space-and-defense-markets-302800258.html

SOURCE Rocket One Inc.

Continue Reading

Technology

SQAIRZ Launches SQAIRZ Medical

Published

on

By

New Division Introduces the First Integrated Balance & Stability Platform to Help Combat Fall Risk and Support Lifelong Movement, Vitality and Independence

WINDHAM, N.H., Sept. 10, 2026 /PRNewswire/ — SQAIRZ, the biomechanically driven performance footwear company built on the belief that performance starts where you stand, today announced the launch of SQAIRZ Medical, extending the company’s expertise in stability and human movement into one of the most significant health challenges facing an aging population: fall risk and the loss of mobility, vitality and independence that can follow.

At the center of the new division is SENTRX™ purpose-built Balance & Stability footwear engineered from the ground up by SQAIRZ to help create a more stable foundation for everyday movement. In addition, SQAIRZ Medical has developed a holistic clinical framework designed to provide a critical continuum of support.

That framework integrates a Balance & Stability Protocol that connects objective fall-risk assessment, SQAIRZ’s biomechanically engineered footwear, individualized clinical intervention, and ongoing outcomes tracking into a single approach that optimizes support at every stage of the balance and stability journey.

The need is urgent. One in four U.S. adults over age 65 falls at least once every year. For adults over 80, the risk increases to one in two. Fall-related injuries account for more than $80 billion in annual U.S. healthcare spending, while also diminishing an individual’s ability to fully engage in the relationships and experiences that define quality of life.

“For more than a decade, SQAIRZ has studied the relationship between the ground, the foot, stability and human performance,” said Bob Winskowicz, Founder and CEO of SQAIRZ. “SQAIRZ Medical represents the next evolution of that work. We believe that better stability should not only help an athlete perform better. It can help people continue living better. Our goal is to identify risk earlier, provide meaningful intervention and help people maintain the movement, confidence and independence that make a full life possible.”

Beyond the Shoe: A Complete Solution

The SQAIRZ Medical approach begins with a simple premise: you cannot effectively address a risk you have not first measured.

Through the SQAIRZ Balance & Stability Program, healthcare providers can use Kinetisense® Risk of Fall and Gait Assessment technology to perform a rapid 3D movement assessment that evaluates walking speed, stride pattern, body sway, compensatory movement and an individual’s fall-risk percentage.

Those insights help inform an individualized stability plan. The SQAIRZ clinical pathway is designed around escalating levels of intervention based on identified risk, ranging from neuromuscular education and baseline guidance for lower-risk patients to appropriate orthopedic solutions.

That includes SENTRX, purpose-built balance and stability footwear engineered with a wider natural base of support, a toe box that allows the toes to spread naturally for better balance, and a high-traction outsole that helps maintain connection with the ground; and, where appropriate, Thrive Orthopedics lateral or anterior AFO bracing. Follow-up testing and outcomes tracking allow providers to reassess patients over time.

Integrates into Clinical Care

SQAIRZ Medical is being developed around the realities of clinical adoption, patient access and reimbursement.

For patients whose assessment indicates a greater need for stabilization, the SQAIRZ clinical pathway incorporates Thrive Orthopedics AFO solutions, including pathways identified in SQAIRZ materials under L1952 and L1933. The broader program is supported with provider education, treatment-pathway guidance, documentation tools, chart-note templates and letters of medical necessity.

SQAIRZ patient materials indicate that SENTRX footwear may be covered through Medicare, depending on patient qualification and coverage. Patients may also have HSA/FSA payment options.

The goal is to create a Balance & Stability solution that can live not only in consumer commerce, but inside real patient-provider workflows.

Built with Medical Expertise

The development of SQAIRZ Medical is supported by a multidisciplinary Medical Advisory Board spanning orthopedics, podiatry, physical therapy, biomechanics, sports medicine and movement science.

The advisory group includes physicians, surgeons, podiatrists, physical therapists, researchers and biomechanics experts with experience across leading medical institutions, professional sports and clinical practice. Their role extends beyond product endorsement, helping inform clinical protocols, research priorities, provider education and the continued development of evidence-based approaches to balance and stability.

“In podiatry and sports medicine, we see every day how much the relationship between the foot and the ground influences balance, confidence and movement,” said Dr. Paul Klutts, DPM, Director of Fellowship for Kentucky and Indiana Foot and Ankle. “What is compelling about SQAIRZ Medical is that it approaches stability as a system: measure risk, create a stronger foundation at the foot and connect that intervention to ongoing clinical care. SENTRX is designed to make that foundation part of everyday life.”

“Fall risk is not a single-variable problem, and it should not be addressed with a single-variable solution,” said Dr. Larry Benz, PT, DPT, OCS, MBA, MAPP, FAPTA, Founder and CEO of Confluent Health. “The opportunity with SQAIRZ Medical is to connect objective assessment, footwear, individualized intervention and outcomes tracking in a way that can fit within the continuum of care. That kind of integrated approach can help clinicians move from reacting to falls toward identifying and addressing risk earlier.”

From Performance Footwear to Performance throughout Life

SQAIRZ Medical represents a natural expansion of the company’s original mission.

SQAIRZ was founded on the belief that performance starts where you stand. Across golf, baseball, softball and pickleball, the company has focused on the relationship between the ground, the foot, stability and human movement. SQAIRZ Medical applies that same foundational thinking to a different stage of life.

“People don’t wake up wanting a stability shoe. They want to keep doing the things they love. They want another walk with their spouse, another vacation, another birthday, another afternoon with their grandchildren. They want to remain active, vital and independent for as long as possible,” Winskowicz said. “That is what we mean by SQAIRZ FOR LIFE. From helping an athlete perform to helping someone maintain their movement and independence as they age, we want SQAIRZ to be The Foundation of Human Movement throughout every stage of life.”

About SQAIRZ

SQAIRZ is a biomechanically driven performance footwear company founded on the principle that performance starts where you stand. Through footwear engineered to enhance stability, ground connection and movement, SQAIRZ serves athletes across golf, baseball, softball, pickleball and now consumers through SQAIRZ Medical. For more information, visit SQAIRZ.com or SQAIRZMedical.com.

View original content:https://www.prnewswire.com/news-releases/sqairz-launches-sqairz-medical-302874411.html

SOURCE SQAIRZ

Continue Reading

Technology

MHK and MCG Partner to Connect Evidence-Based Clinical Guidance with Standards-Based Prior Authorization

Published

on

By

New integration to help health plans streamline prior authorization and prepare for CMS-0057-F compliance

SEATTLE, Sept. 10, 2026 /PRNewswire/ — MCG Health, part of the Hearst Health network and the industry’s source of truth for trusted clinical guidance, announces a newly certified integration with MHK, a leading healthcare technology provider and a sibling Hearst Health company. The new integration connects the MCG Path interoperability solution directly with the MHK CareProminence prior authorization workflow, helping health plans streamline authorization processes while supporting standards-based interoperability required by the CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F).

The prior authorization process has historically required healthcare providers and health plans to navigate separate clinical, documentation, and administrative requirements. When required clinical information is not clearly identified at the point of request, submissions may be incomplete, resulting in requests for additional information, manual follow-up, longer review cycles, and ultimately, delayed care for members. Simultaneously, health plans seek to balance adapting their current utilization management workflows to the evolution of standards-based interoperability.

The new MHK CareProminence and MCG Path integration brings highly trusted clinical guidance and documentation requirements directly into the authorization workflow, connecting capabilities that have traditionally operated as separate steps. Using HL7® Da Vinci Project burden reduction standards – including Coverage Requirements Discovery (CRD), Documentation Templates and Rules (DTR), and Prior Authorization Support (PAS) – the integration surfaces evidence-based MCG clinical indications and structured documentation requirements at the point of a prior authorization request.

The integration is designed to help health plans:

Support evidence-based decision-making by incorporating the nationally recognized MCG care guidelines into the prior authorization workflowReduce administrative burden by helping providers identify and submit required clinical documentation earlier in the processPromote more consistent reviews by making structured clinical requirements available within existing workflowsAdvance interoperability readiness by supporting HL7 Da Vinci standards associated with CMS-0057-F API requirements that are primarily due January 1, 2027

One of the first to utilize the MHK-MCG integration will be Mountain Pacific, a multi-state nonprofit organization with a long history of innovation and healthcare quality improvement.

“We’re excited to integrate MHK CareProminence and MCG into our medical necessity review process for prior authorization as part of our continued commitment to modernizing healthcare delivery,” said Jill Alessi, Chief Executive Officer at Mountain Pacific. “By connecting trusted, nationally recognized, evidence-based clinical guidelines with clearer documentation requirements, this integration has the potential to reduce administrative burden, streamline the review process, facilitate timely care, strengthen collaboration, and support a more efficient experience for providers and their patients.”

“Prior authorization works best when clinical guidance, documentation requirements, and the authorization workflow are connected rather than operating as separate steps,” said Carol Helton, COO of MHK. “Bringing MCG’s trusted clinical guidance directly into CareProminence enables health plans to simplify that process while giving providers clearer information at the point of request. Equally important, this integration gives our customers a practical path toward the standards-based interoperability required under CMS-0057-F.”

“We’re seeing tremendous momentum for MCG Path as health plans across the country prepare for the next era of interoperable prior authorization,” said Jon Shreve, President and CEO of MCG Health. “Our partnership with MHK is a critical part of that progress, bringing the trust of MCG directly into the workflows health plans already use. Together, we’re driving more confident decisions that help patients get the right care.”

The certified MHK-MCG interoperability integration is currently available to health plans, and demonstrations can be requested via the MHK and MCG websites at mhk.com/contact/schedule-a-demo/ or mcg.com/contact-us/schedule-a-demo/.

About MCG Health

MCG, part of the Hearst Health network, is the trusted source of truth for clinical guidance in the healthcare industry. MCG combines evidence-based guidelines and analytics with artificial intelligence to guide efficient and accurate clinical decisions. MCG solutions are licensed by a vast majority of health plans, thousands of hospitals, and many state and federal government agencies to drive quality health outcomes while controlling costs. For more information, visit mcg.com.

About MHK

MHK, formerly MedHOK, is a leading provider of healthcare SaaS solutions for health plans, pharmacy benefit managers, and provider-sponsored organizations. MHK’s platforms support utilization management, case management, population health, pharmacy management, enrollment, and compliance. Headquartered in Tampa, Fla., MHK partners with payers nationwide to optimize operations, improve outcomes, and deliver superior member experiences. For more information, visit mhk.com.

About Mountain Pacific

Established in 1973, Mountain Pacific has decades of experience collaborating with healthcare professionals, consumers and communities across multiple states to deliver innovative solutions. Through federal, state and commercial funding and partnerships, Mountain Pacific brings national public health priorities to the local level to achieve better health outcomes, lower costs, greater access to high-quality care and improved patient experiences. Learn more at mountainpacific.org.

View original content to download multimedia:https://www.prnewswire.com/news-releases/mhk-and-mcg-partner-to-connect-evidence-based-clinical-guidance-with-standards-based-prior-authorization-302868125.html

SOURCE MCG Health

Continue Reading

Technology

NuxGame Heads to SBC Summit Lisbon 2026 With Its Full Ecosystem and a Seat on the Compliance Stage

Published

on

By

LIMASSOL, Cyprus, Sept. 10, 2026 /PRNewswire/ — NuxGame, a B2B iGaming software provider, will take part in SBC Summit Lisbon 2026, held from Sept. 29 to Oct. 1 at the Feira Internacional de Lisboa. The team will be based at Stand A326 in Hall 1, the event’s Networking Lounge sponsored by NuxGame, where operators can sit down with senior staff from the product and commercial teams.

From Software Provider to Open Ecosystem

The timing suits where the business now stands. NuxGame began in 2018 as a software provider for operators launching their first projects, and today it runs an open ecosystem built around operator growth. Lisbon is one of the few occasions in the year when all of it can be seen in one place, by the people who would use it day to day.

What Operators Will See at Stand A326

Across the three days, the team will walk operators through the NuxGame Ecosystem in full:

An award-winning turnkey casino and sportsbook platform.

A game aggregator with 18,500+ titles from 140+ providers.

Sweepstakes-ready infrastructure.

A vetted network of partners covering CRM, payments, orchestration, and traffic.

That last part saves time. Instead of assessing vendors market by market, operators plug into partners already working in the regions they are entering, with the software underneath coming from a single provider. It is all backed by a service team whose client satisfaction has averaged 4.8 out of 5 over the past six months.

Denis Kosinsky on the Compliance Tech Stage

On Thursday, Oct. 1, NuxGame Chief Product Officer Denis Kosinsky will join the panel “Closing the Loopholes: How to Combat Bonus Abuse” on the Regulation & Compliance stage, part of the summit’s new Compliance Tech track. The session looks at how operators can recognize evolving patterns of bonus exploitation and keep promotional spend flowing to the players it was designed for.

“A bonus budget is one of the most powerful growth tools an operator has, and it works best when the money reaches genuine players. The instinct is to tighten the rules for everyone, but that’s like locking the whole building because one window doesn’t shut. Better to find the window. When you can see clearly how a promotion is actually being used, you close that one gap and leave the offer generous for everybody else.”

— Denis Kosinsky, Chief Product Officer at NuxGame

Book a Meeting in Lisbon

“Lisbon is where a lot of operators decide what their next year looks like. We wanted a space where those conversations can happen properly, with the platform, the content, and the partner network all in the room at once. Twenty minutes with the right people will tell you more than three months of comparing suppliers on paper.”

— Daniel Heywood, Chief Executive Officer at NuxGame

Operators, affiliates, and partners attending the summit can book a meeting with the NuxGame team in advance, or stop by Stand A326 in Hall 1 on any of the three days.

About NuxGame

NuxGame is a B2B iGaming company founded in 2018 that has grown from a software provider into an open ecosystem for operator growth. It combines an award-winning casino and sportsbook platform, a game aggregator with 18,500+ titles from 140+ providers, sweepstakes-ready infrastructure, and a vetted network of partners covering CRM, payments, orchestration, and traffic, supporting 100+ operators worldwide as they launch, scale, and enter new markets. In 2026, NuxGame was named Casino Platform of the Year at the iGaming News Awards. Visit https://nuxgame.com/ for more information and inquiries.

Media Contact: Yanina Kaplya, CMO at NuxGame, info@nuxgame.com

Original Source: https://nuxgame.com/blog/nuxgame-sbc-summit-lisbon-2026

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuxgame-heads-to-sbc-summit-lisbon-2026-with-its-full-ecosystem-and-a-seat-on-the-compliance-stage-302875384.html

SOURCE NuxGame

Continue Reading

Trending